COSMC Is Overexpressed in Proliferating Infantile Hemangioma and Enhances Endothelial Cell Growth via VEGFR2

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Lee, Jian Jr ^a,d   Chen, Chia Hua ^a   Chen, Ya Hsin ^a   Huang, Miao Juei ^a,b   Huang, John ^c   Hung, Ji Shiang ^c   Chen, Ming Ting ^d   Huang, Min Chuan ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CHAPERONE; COSMC PROTEIN; GLYCAN DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; T ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CAPILLARY HEMANGIOMA; CELL GROWTH; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION;

ANTIGENS, VIRAL, TUMOR; CELL PROLIFERATION; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLYCOSYLATION; HEMANGIOMA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFANT; MOLECULAR CHAPERONES; PHOSPHORYLATION; PROTEOLYSIS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84873703055     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056211     Document Type: Article

References (22)

1. Kilcline C, Frieden IJ, (2008) Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatric dermatology 25: 168-173.
2. Drolet BA, Esterly NB, Frieden IJ, (1999) Hemangiomas in children. The New England journal of medicine 341: 173-181.
3. Histopathology of vascular anomalies. 38: 31-44.
4. Robinson CJ, Stringer SE, (2001) The splice variants of vascular endothelial growth factor (VEGF) and their receptors. Journal of cell science 114: 853-865.
5. Jinnin M, Medici D, Park L, Limaye N, Liu Y, et al. (2008) Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nature medicine 14: 1236-1246.
6. Tarp MA, Clausen H, (2008) Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta 1780: 546-563.
7. Astronomo RD, Burton DR, (2010) Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov 9: 308-324.
8. Tian E, Ten Hagen KG, (2009) Recent insights into the biological roles of mucin-type O-glycosylation. Glycoconj J 26: 325-334.
9. Ju T, Brewer K, D'Souza A, Cummings RD, Canfield WM, (2002) Cloning and expression of human core 1 beta1,3-galactosyltransferase. J Biol Chem 277: 178-186.
10. Ju T, Otto VI, Cummings RD, (2011) The Tn antigen-structural simplicity and biological complexity. Angewandte Chemie (International ed in English) 50: 1770-1791.
11. Xia L, McEver RP, (2006) Targeted disruption of the gene encoding core 1 beta1-3-galactosyltransferase (T-synthase) causes embryonic lethality and defective angiogenesis in mice. Methods Enzymol 416: 314-331.
12. Wang Y, Ju T, Ding X, Xia B, Wang W, et al. (2010) Cosmc is an essential chaperone for correct protein O-glycosylation. Proceedings of the National Academy of Sciences of the United States of America 107: 9228-9233.
13. Fu J, Gerhardt H, McDaniel JM, Xia B, Liu X, et al. (2008) Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice. The Journal of clinical investigation 118: 3725-3737.
14. Wu YM, Liu CH, Hu RH, Huang MJ, Lee JJ, et al. (2011) Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor. Cancer Res 71: 7270-7279.
15. Ju T, Aryal RP, Stowell CJ, Cummings RD, (2008) Regulation of protein O-glycosylation by the endoplasmic reticulum-localized molecular chaperone Cosmc. J Cell Biol 182: 531-542.
16. Yu LG, (2007) The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression. Glycoconj J 24: 411-420.
17. Heimburg-Molinaro J, Lum M, Vijay G, Jain M, Almogren A, et al. (2011) Cancer vaccines and carbohydrate epitopes. Vaccine 29: 8802-8826.
18. Fuster MM, Esko JD, (2005) The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 5: 526-542.
19. Holmes K, Roberts OL, Thomas AM, Cross MJ, (2007) Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19: 2003-2012.
20. Yu Y, Varughese J, Brown LF, Mulliken JB, Bischoff J, (2001) Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. The American journal of pathology 159: 2271-2280.
21. Berard M, Sordello S, Ortega N, Carrier JL, Peyri N, et al. (1997) Vascular endothelial growth factor confers a growth advantage in vitro and in vivo to stromal cells cultured from neonatal hemangiomas. The American journal of pathology 150: 1315-1326.
22. Walter JW, North PE, Waner M, Mizeracki A, Blei F, et al. (2002) Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes, chromosomes & cancer 33: 295-303.